|06 October, 2018

Neopharma acquires a manufacturing facility in US

Neopharma has five globally accredited pharmaceutical manufacturing facilities in three continents

Image used for illustrative purpose. Smiling pharmacist with commissioning machine in pharmacy.

Image used for illustrative purpose. Smiling pharmacist with commissioning machine in pharmacy.

Getty Images

Neopharma Inc., USA, a subsidiary of Abu Dhabi based UAE' largest pharmaceutical manufacturer, Neopharma LLC, announced that in a 100 per cent ownership transfer, it has acquired from Dr. Reddy's Laboratories, Inc. a subsidiary of Dr. Reddy's Laboratories Ltd., which is an antibiotic manufacturing facility and its related assets in Bristol, Tennessee (US).

The Bristol site has had a long history first with the British drug maker GlaxoSmithKline (GSK) and then with Dr. Reddy's in manufacturing the brands Augmentin and Amoxil. The sale will enable the facility to continue providing oral penicillin-containing antibacterial products to patients in the United States. The 390,000-square-foot facility is dedicated to manufacturing and packaging oral-solid dose penicillin and has separate spaces for processing, packaging, development, printing, and warehousing.

Currently, Neopharma has five globally accredited pharmaceutical manufacturing facilities in three continents and serves over 50 countries with more than 100 different products.

Suresh Kumar Nandiraju, Chief Operating Officer of Neopharma, said, "This acquisition allows us to enter the United States penicillin-containing antibiotic market segment and marks our entry into the generic drug business in the US, while providing opportunities to explore additional synergies with our other group companies. The acquisition will help us leverage our expertise in beta lactam manufacturing segment."

Beta lactam is a class of broad-spectrum antibiotics, consisting of all antibiotic agents that contain a beta-lactam ring in their molecular structures.

Copyright © 2018 Khaleej Times. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Equities